Based on the above-presented data, the role of GLP-1 RA and SGLT2 inhibitor therapy is well established in reducing cardiovascular risk in patients with type 2 diabetes mellitus. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.